Loading...
Docoh

CASI Pharmaceuticals (CASI)

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.

Company profile

Ticker
CASI
Exchange
CEO
Wei-Wu He
Employees
Incorporated
Location
Fiscal year end
Former names
ENTREMED INC
SEC CIK
Subsidiaries
CASI Pharmaceuticals (China) Co., Ltd, a company of limited • Beijing Zhongbai Biotechnology Co., Ltd. • Miikana Therapeutics, Inc. • CASI Biopharmaceuticals (WUXI) Co., Ltd., a company of limited • CASI Pharmaceuticals (WUXI) Co., Ltd., a company of limited • CASI Pharmaceuticals (Hainan) Co., Ltd., a company of limited ...
IRS number
581959440

CASI stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 May 22
17 May 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 29.26M 29.26M 29.26M 29.26M 29.26M 29.26M
Cash burn (monthly) 3.15M 3.24M 2.8M 2.89M 1.41M 1.92M
Cash used (since last report) 4.89M 5.03M 4.35M 4.49M 2.2M 2.99M
Cash remaining 24.37M 24.23M 24.91M 24.77M 27.06M 26.27M
Runway (months of cash) 7.7 7.5 8.9 8.6 19.2 13.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 Dec 21 Alexander A Zukiwski Employee Stock Option Common Stock Grant Dispose A No No 0.87 500,000 435K 500,000
18 Nov 21 He Wei-Wu Common Stock Buy Acquire P No No 0.98 200,000 196K 5,558,472
17 Nov 21 He Wei-Wu Common Stock Buy Acquire P No No 0.99 200,000 198K 5,362,569
19 Aug 21 He Wei-Wu Common Stock Buy Acquire P No No 1.26 180,000 226.8K 5,163,994
18 Aug 21 He Wei-Wu Common Stock Buy Acquire P No No 1.29 300,000 387K 4,983,994
24 Jul 21 Zhang Larry Employee Stock Option Common Stock Grant Dispose A No No 1.28 800,000 1.02M 800,000
15 Jun 21 Salisbury Franklin Cary jr Stock Option Common Stock Grant Acquire A No No 1.65 110,459 182.26K 110,459
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change

Financial report summary

?
Management Discussion
  • Product sales consist of sales of EVOMELA® that launched during August 2019. Revenue was $9.0 million for the three months ended March 31, 2022 compared to $5.7 million for the three months ended March 31, 2021. Revenues increased by 58% in the first quarter of 2022 as compared to same quarter in 2021 due to the continued growth in EVOMELA® sales.  
  • Lease income consists primarily of an equipment lease with Juventas (a related party). Lease income was $37,000 and $36,000, respectively, for the three months ended March 31, 2022 and 2021.
  • Cost of revenues consists primarily of the cost of inventories of EVOMELA® and sales-based royalties related to the sale of EVOMELA®.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accredited, America, analogy, approximately, Assistance, ASU, attributable, auditor, Barcelona, bid, bill, billion, BioHealth, CDE, Center, certainty, CNCT, consecutive, create, CRPCGIT, CTA, cytotoxic, enhance, esteve, expenditure, FASB, firm, follicular, founder, France, Genetic, Group, guidance, haemopoietic, headquartered, Healthcare, HFCAA, HGRAC, IA, inspect, inspection, issuance, led, mantle, manufactory, marginal, notify, passed, PCAOB, permitted, PK, PRC, prohibit, prohibited, prohibition, prospectively, provision, Recommended, registered, rely, repurchase, repurchased, restriction, retrospectively, revision, run, satisfy, scientific, Senate, shutdown, Spain, stage, submit, submitted, suggested, terminated, threat, Topic, unanticipated, unpaid, withdrawal
Removed: accessible, Accretion, achievement, acquire, activity, addressing, adult, Aid, allocated, Allocation, alternate, annualized, annum, appointed, arise, arrangement, Article, assume, attend, audited, automatically, award, bankruptcy, bear, behalf, BioCheck, book, Branch, build, California, call, candidate, capitalized, carrier, CCA, Chartwell, CITIC, cloud, collected, combined, comparable, compensating, confidence, considerable, consideration, consisting, consolidation, constraint, continuing, controlling, converted, conveyed, Corporation, CRGK, customer, data, decline, deemed, delayed, depend, derecognized, derived, designated, director, disbursed, discontinued, disease, disposal, dissolution, distancing, divided, dividend, dosing, Dr, duty, Electronic, eliminated, embedded, enactment, Engineering, enrollment, Enterprise, entitled, entity, estimable, estimation, evidenced, execution, expired, factor, factory, federal, fixed, Flexibility, forgiven, framework, funded, gain, granted, guarantee, guaranteed, guard, Guokang, HCW, health, hierarchical, highest, holder, Huicun, identification, Incentive, increasing, Industry, infection, influence, initially, initiation, institution, instrument, Jintou, lab, large, lead, lender, life, line, liquidation, loan, lowest, mandated, mandatorily, mandatory, manufacturer, marketed, MaxCyte, maximum, measuring, meet, member, method, microtubule, Miikana, monthly, negatively, newly, observability, observer, occur, occurred, orderly, ordinary, Organization, organized, ownership, parent, participant, partnership, pattern, paused, Paycheck, percent, performance, permanent, Ph, pharmacology, Philadelphia, planned, PPP, PPPFA, predicted, preference, preferred, presentation, prioritization, priority, privately, progressed, prolongation, promissory, protocol, put, quarantine, radiotherapeutic, rational, read, receive, receiving, recognition, recognize, record, recruitment, redeem, Regulation, relapse, relevant, Relief, remain, represented, requisite, resolved, retain, retroactive, reverse, review, round, Rx, SBA, security, segment, SEK, selected, service, settle, settled, shareholder, sheet, shipment, site, social, space, speak, split, state, stated, stipulated, stipulation, stockholder, subscribe, subsequently, subsidiary, substantive, summary, susceptible, systematic, temporary, tranche, transaction, transfer, transferred, travel, treat, type, unadjusted, unfold, unit, unsecured, vendor, vesting, voting, yield